Becerra assures vaccine makers: HHS will continue purchasing.

Department of Health and Human Services Continues to Prioritize COVID-19 Response

Secretary Xavier Becerra of the Department of Health and Human Services (HHS) sent a letter on Thursday to COVID-19 vaccine manufacturers, emphasizing the federal government’s commitment to purchasing vaccines in advance for the upcoming 2023-2024 seasonal cycle. This demonstrates the Biden-Harris Administration’s dedication to public health and the ongoing fight against the pandemic.

“The COVID-19 response remains a significant public health priority for the Biden-Harris Administration and HHS,” wrote Becerra. “The relationship with HHS and the manufacturers continues to evolve as the U.S. government moves into this next phase of our response, but your innovation and expertise will continue to be important to develop, manufacture, and help to ensure equitable access to lifesaving products going forward.”

FTC Investigating ChatGPT Over False Information Allegations

In other news, the Federal Trade Commission (FTC) is currently investigating ChatGPT for allegedly publishing false information that may have harmed consumers. This highlights the importance of accurate and reliable sources of information during these challenging times.

HHS Ensures Access to COVID-19 Vaccines and Treatment for Uninsured Individuals

In April, HHS announced a plan to provide access to COVID-19 vaccines and treatment for uninsured individuals. This plan involves a unique partnership with pharmacy chains to ensure continued access to government-subsidized anti-coronavirus products.

Becerra further clarified the details of this plan in the letter sent on Thursday, stating that the CDC will purchase the vaccines through the agency’s authority under Section 317 of the Public Health Service Act.

It is crucial for manufacturers to have their supply ready by the later part of September to facilitate necessary actions by the Food and Drug Administration and the Centers for Disease Control and Prevention for the 2023-2024 COVID-19 vaccination campaign.

During an FDA meeting in June, Peter Marks, the Director of the Center for Biologics Evaluation, mentioned that the new vaccines covering the XBB1.5 strain should be rolled out in September, considering supply and regulatory factors.

Becerra emphasized the importance of accurate and timely data in facilitating equitable access to COVID-19 products. Sharing information with government partners is essential to uphold the shared goal of equity.

Furthermore, Becerra warned that prices for vaccines and treatment must be kept reasonable. Companies should collaborate with insurance providers and the Centers for Medicare and Medicaid Services to determine a fair market price for these products.

Updated COVID-19 vaccines entering the market this fall should be priced at a reasonable rate, reflective of the value that you have obtained through U.S. government investment. Price gouging behavior takes advantage of the trust the American people have placed in you through the COVID-19 response,” wrote Becerra.

As of May, only 22% of adults remained “very concerned” about the state of COVID-19, indicating a shift in public sentiment as vaccination efforts continue.

Click here to read more from The Washington Examiner.

*As an Amazon Associate I earn from qualifying purchases